Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Ionis reports second quarter 2020 financial results and recent business achievements

      On track to achieve 2020 objectives and financial guidance

      Webcast today, August 5, 2020, at 11:30 a.m. Eastern Time

      (PRNewsfoto/Ionis Pharmaceuticals, Inc.)

      News provided by

      Ionis Pharmaceuticals, Inc.

      Aug 05, 2020, 07:00 ET

      Share this article

      Share this article


      CARLSBAD, Calif., Aug. 5, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the second quarter of 2020 and recent business highlights.

      "The first half of this year was marked by numerous important achievements. Our Phase 3 programs progressed, we advanced our cardio-renal, metabolic and neurological disease franchises and added new medicines to our Ionis-owned pipeline. Together, these catalysts moved us closer to delivering 10 or more marketing applications through 2025, which we expect to result in a number of new commercial medicines. In the second half of this year, we are expanding the reach of our technology in neurological and pulmonary diseases, as studies in sporadic ALS and COPD get underway. We also look forward to proof-of-concept data from additional mid-stage programs," said Brett P. Monia, Ph.D., chief executive officer at Ionis. "Our achievements, together with our significant financial resources, position us to realize my vision for Ionis – to lead in the delivery of transformational medicines for patients around the world."

      Second Quarter 2020 Financial Results and Highlights

      • On track to achieve financial guidance of being meaningfully profitable this year
        • Net income of $8 million on a non-GAAP basis and a net loss of $32 million on a GAAP basis
      • Achieved quarter over quarter growth in commercial and R&D revenues
        • Commercial revenue from SPINRAZA® (nusinersen) royalties increased to $72 million
        • Product sales from TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen) increased to $16 million
        • R&D revenue increased to more than $55 million, including $26 million from Ionis' neurological disease franchise, $13 million from the oncology franchise and more than $10 million from the cardio-renal franchise
      • Cash position of more than $2.3 billion provides substantial financial resources to continue executing on strategic goals

      "We ended the second quarter with net income on a non-GAAP basis, an increase compared to our first quarter results. Looking ahead, we are maintaining our 2020 financial guidance and expect revenue and earnings growth in the second half of this year. With our substantial resources, we are well positioned to continue executing on our ambitious agenda and to deliver increasing value near-term and into the future," said Elizabeth L. Hougen, chief financial officer of Ionis.

      All non-GAAP amounts referred to in this press release exclude non-cash compensation expense related to equity awards. Please refer to the reconciliation of non-GAAP and GAAP measures, which is provided later in this release.

      Commercial Medicine Highlights

      • SPINRAZA: a global foundation-of-care for the treatment of spinal muscular atrophy (SMA) patients of all ages
        • $495 million in worldwide sales in the second quarter of this year
        • More than 11,000 patients were on SPINRAZA treatment worldwide at the end of the second quarter, including patients across commercial, expanded access and clinical trial settings
        • The Phase 4 RESPOND study to evaluate SPINRAZA benefit in patients with a suboptimal clinical response to Zolgensma® (onasemnogene abeparvovec) is expected to begin early next year
        • The DEVOTE study evaluating a higher dose of SPINRAZA with the potential to deliver even greater efficacy in SMA patients of all ages is progressing
        • New clinical data from the NURTURE and SHINE studies, as well as new real-world data, further support SPINRAZA's durable efficacy and established safety profile across SMA patients of all ages
      • TEGSEDI: the only approved at-home subcutaneous therapy for the treatment of hereditary transthyretin amyloidosis (hATTR) with polyneuropathy in adult patients
        • Commercially available in 15 countries
        • Reimbursement approved in Portugal, Spain, Italy and Austria
        • Expanding commercial availability in additional EU countries and in Latin America this year
      • WAYLIVRA: the only approved treatment in the EU for adults with genetically confirmed familial chylomicronemia syndrome (FCS) at high risk for pancreatitis
        • Launch progressing in Germany, Austria, Greece and through the ATU in France; launching in additional EU countries this year
        • Filed for marketing approval in Brazil; refiling new drug application for U.S. marketing authorization

      Second Quarter 2020 and Recent Pipeline Highlights

      • Completed enrollment in the global GENERATION HD1 Phase 3 study of tominersen in patients with Huntington's disease
      • Progressed multiple neurological disease medicines under Ionis' broad Biogen collaboration
        • Published data from the Phase 1/2 study of tofersen in the New England Journal of Medicine
        • Progressed the IONIS-MAPTRx long-term extension study in patients with Alzheimer's disease and achieved a $12 million milestone payment
        • Advanced ION464 into a Phase 1/2 study in patients with multiple system atrophy and achieved an $18 million milestone payment
      • Advanced medicines for the treatment of cancer and immune-mediated GI disease
        • Licensed ION736 to AstraZeneca for the treatment of cancer and achieved a $13 million license fee
        • Initiated a Phase 1 study of ION253 for the treatment of immune-mediated GI disease and achieved a $5 million milestone payment from Janssen
      • Expanded the Ionis-owned pipeline with the addition of ION363 for the treatment of FUS-ALS

      Upcoming Catalysts 

      • Report clinical proof-of-concept results for four or more programs
      • Present positive Phase 2 results from vupanorsen and AKCEA-APOCIII-LRx
      • Initiate a Phase 3 study of AKCEA-APOCIII-LRx in patients with FCS
      • Initiate a registration study of ION363 in patients with FUS-ALS
      • Initiate a Phase 1/2 study of ION541 in patients with sporadic ALS
      • Initiate a Phase 2 study of IONIS-ENaC-2.5Rx in patients with chronic obstructive pulmonary disease (COPD)
      • Initiate a Phase 2 study of IONIS-FXI-LRx in patients with clotting disorders
      • Initiate a Phase 2 study of IONIS-HBVRx in patients with hepatitis B virus infection
      • Advance additional new medicines into development

      Revenue

      Ionis' revenue was comprised of the following (amounts in millions):



      Three months ended,


      Six months ended



      June 30,


      June 30,



      2020


      2019


      2020


      2019

      Revenue:







           Commercial revenue:









      SPINRAZA royalties


      $72


      $71


      $138


      $130

      Product sales, net


      16


      10


      32


      17

      Licensing and royalty revenue


      2


      7


      4


      9

      Total commercial revenue


      90


      88


      174


      156

      R&D Revenue:









      Amortization from upfront payments


      28


      41


      49


      75

      Milestone payments


      7


      12


      30


      52

      License fees


      15


      22


      15


      173

      Other services


      6


      1


      11


      5

      Total R&D revenue


      56


      76


      105


      305

      Total revenue


      $146


      $164


      $279


      $461

      Operating Expenses

      Ionis' operating expenses for the second quarter of 2020 increased compared to the same period in 2019 driven by its investments in advancing its strategic priorities, including advancing the Phase 3 program for AKCEA-TTR-LRx and other medicines in its Ionis-owned pipeline.  

      Net Loss Attributable to Noncontrolling Interest in Akcea

      At June 30, 2020, Ionis owned approximately 76 percent of Akcea. The Company's net loss attributable to noncontrolling interest in Akcea for the second quarter of 2020 was consistent with the same period last year. The line titled "Net loss attributable to noncontrolling interest in Akcea" on Ionis' statement of operations reflects the portion of Akcea's net income or loss attributable to the other owners of Akcea's common stock.

      Net Income (Loss) Attributable to Ionis Common Stockholders

      Ionis' net loss attributable to Ionis' common stockholders for the second quarter of 2020 was larger compared to the same period in 2019 primarily due to higher revenue and lower operating expenses in the same period last year.

      Balance Sheet

      Ionis ended June 2020 with cash, cash equivalents and short-term investments of more than $2.3 billion, compared to $2.5 billion at December 31, 2019.

      Webcast

      Today, at 11:30 a.m. Eastern Time, Ionis will conduct a live webcast to discuss this earnings release and related activities. Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address.

      About Ionis Pharmaceuticals, Inc.

      As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of diseases, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.

      To learn more about Ionis visit www.ionispharma.com or follow us on twitter @ionispharma.

      Ionis' Forward-looking Statement

      This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of SPINRAZA (nusinersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' majority-owned affiliate. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2019, and the most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available from the Company.

      In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

      Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA® is a registered trademark of Biogen. 

      Ionis Pharmaceuticals Investor Contact:
      D. Wade Walke, Ph.D.
      Vice President, Investor Relations
      760-603-2741

      Ionis Pharmaceuticals Media Contact:
      Roslyn Patterson
      Vice President, Corporate Communications
      760-603-2681


      IONIS PHARMACEUTICALS, INC.

      SELECTED FINANCIAL INFORMATION

      Condensed Consolidated Statements of Operations

      (In Millions, Except Per Share Data)




      Three months ended


      Six months ended



      June 30,


      June 30,



      2020


      2019


      2020


      2019










      (unaudited)

      Revenue:









           Commercial revenue:









      SPINRAZA royalties


      $72


      $71


      $138


      $130

      Product sales, net


      16


      10


      32


      17

      Licensing and royalty revenue


      2


      7


      4


      9

      Total commercial revenue


      90


      88


      174


      156

          Research and development revenue under collaborative agreements


      56


      76


      105


      305

      Total revenue


      146


      164


      279


      461

      Expenses:









             Cost of products sold


      3


      1


      6


      2

          Research, development and patent


      122


      106


      239


      213

          Selling, general and administrative


      73


      76


      147


      143

      Total operating expenses


      198


      183


      392


      358










      Income (loss) from operations


      (52)


      (19)


      (113)


      103










      Other income, net


      8


      2


      7


      2

      Income (loss) before income tax benefit (expense)


      (44)


      (17)


      (106)


      105



















      Income tax benefit (expense)


      -


      7


      4


      (24)










      Net income (loss)


      $(44)


      $(10)


      $(102)


      $81

      Net loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.


      12


      9


      22


      3

      Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders


      $(32)


      $(1)


      $(80)


      $84










      Basic net income (loss) per share


      $(0.23)


      $(0.01)


      $(0.58)


      $0.62

      Diluted net income (loss) per share


      $(0.23)


      $(0.01)


      $(0.58)


      $0.61

      Shares used in computing basic net income (loss) per share


      139


      140


      139


      139

      Shares used in computing diluted net income (loss) per share


      139


      140


      139


      142


      IONIS PHARMACEUTICALS, INC.
      SELECTED FINANCIAL INFORMATION

      Condensed Consolidating Statement of Operations

      (In Millions)




       Six months ended
      June 30, 2020
      (unaudited)



      Ionis


      Akcea


      Eliminations


      Ionis
      Consolidated

      Revenue:



           Commercial revenue:









      SPINRAZA royalties

      $

      $138


      $-


      $-


      $138

      Product sales, net


      -


      32


      -


      32

      Licensing and royalty revenue


      4


      -


      -


      4

      Total commercial revenue


      142


      32


      -


      174

          Research and development revenue under collaborative agreements


      98


      7


      -


      105

          Intercompany revenue


      7


      -


      (7)


      -

      Total revenue


      247


      39


      (7)


      279

      Expenses:









             Cost of products sold


      -


      10


      (4)


      6

          Research, development and patent expenses


      197


      47


      (5)


      239

          Selling, general and administrative


      59


      88


      -


      147

      Profit/ loss share for TEGSEDI commercialization activities


      10


      (10)


      -


      -

      Total operating expenses


      266


      135


      (9)


      392










      Loss from operations


      (19)


      (96)


      2


      (113)










      Other income, net


      4


      3


      -


      7

      Loss before income tax benefit


      (15)


      (93)


      2


      (106)










      Income tax benefit


      3


      1


      -


      4










      Net loss


      $(12)


      $(92)


      $2


      $(102)

      Net loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.


      $-


      $-


      $22


      $22

      Net loss attributable to Ionis Pharmaceuticals, Inc. common stockholders


      $(12)


      $(92)


      $24


      $(80)


      IONIS PHARMACEUTICALS, INC.

      Reconciliation of GAAP to Non-GAAP Basis:

      Condensed Consolidated Operating Expenses, Income (Loss) From Operations, and Net Income (Loss)

      (In Millions)




      Three months ended

      June 30,


      Six months ended
      June 30,



      2020


      2019


      2020


      2019



      (unaudited)

      As reported research, development and patent expenses according to GAAP


      $122


      $106


      $239


      $213

          Excluding compensation expense related to equity awards      


      (26)


      (24)


      (52)


      (49)










      Non-GAAP research, development and patent expenses


      $96


      $82


      $187


      $164

      As reported selling, general and administrative expenses according to GAAP


      $73


      $76


      $147


      $143

          Excluding compensation expense related to equity awards      


      (22)


      (18)


      (37)


      (39)










      Non-GAAP selling, general and administrative expenses


      $51


      $58


      $110


      $104

      As reported operating expenses according to GAAP


      $198


      $183


      $392


      $358

          Excluding compensation expense related to equity awards      


      (48)


      (42)


      (89)


      (87)










      Non-GAAP operating expenses


      $150


      $141


      $303


      $271










      As reported income (loss) from operations according to GAAP


      $(52)


      $(19)


      $(113)


      $103

          Excluding compensation expense related to equity awards


      (48)


      (42)


      (89)


      (87)

      Non-GAAP income (loss) from operations


      $(4)


      $23


      $(24)


      $190

      As reported net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders according to GAAP


      $(32)


      $(1)


      $(80)


      $84

      Excluding compensation expense related to equity awards attributable to Ionis Pharmaceuticals, Inc. common stockholders


      (45)


      (39)


      (84)


      (78)

      Income tax effect related to compensation expense related to equity awards attributable to Ionis Pharmaceuticals, Inc. common stockholders


      5


      14


      11


      13

      Non-GAAP net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders according to GAAP


      $8


      $24


      $(7)


      $149

      Reconciliation of GAAP to Non-GAAP Basis

      As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP income (loss) from operations, and non-GAAP net income (loss) attributable to Ionis Pharmaceuticals, Inc. common shareholders were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effect. Compensation expense related to equity awards are non-cash. Ionis has regularly reported non-GAAP measures for operating results as non-GAAP results. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.  

      IONIS PHARMACEUTICALS, INC.

      Condensed Consolidated Balance Sheets

      (In Millions)








      June 30,


      December 31,



      2020


      2019



      (unaudited)



      Assets:





        Cash, cash equivalents and short-term investments


      $2,349


      $2,500

        Contracts receivable


      28


      63

        Other current assets


      155


      158

        Property, plant and equipment, net


      173


      154

        Other assets


      374


      358

           Total assets


      $3,079


      $3,233






      Liabilities and stockholders' equity:





        Other current liabilities


      $132


      $155

        Current portion of deferred contract revenue


      100


      118

        0.125% convertible senior notes


      445


      435

        1% convertible senior notes


      284


      275

        Long-term obligations, less current portion


      75


      75

        Long-term deferred contract revenue


      448


      490

        Total Ionis stockholders' equity


      1,377


      1,471

        Noncontrolling interest in Akcea Therapeutics, Inc.


      218


      214

        Total stockholders' equity


      $1,595


      $1,685

          Total liabilities and stockholders' equity


      $3,079


      $3,233







      IONIS PHARMACEUTICALS, INC.

      Condensed Consolidating Balance Sheet

      (In Millions)




      June 30, 2020

      (unaudited)









      Ionis



      Ionis


      Akcea


      Eliminations


      Consolidated










      Assets:









        Cash, cash equivalents and short-term investments


      $1,959


      $390


      $-


      $2,349

        Contracts receivable


      14


      14


      -


      28

        Other current assets


      136


      24


      (5)


      155

        Property, plant and equipment, net


      167


      6


      -


      173

        Other assets


      1,122


      94


      (842)


      374

           Total assets


      $3,398


      $528


      $(847)


      $3,079










      Liabilities and stockholders' equity:









        Other current liabilities


      $102


      $35


      $(5)


      $132

        Current portion of deferred contract revenue


      100


      -


      -


      100

        0.125% convertible senior notes


      445


      -


      -


      445

        1% convertible senior notes


      284


      -


      -


      284

        Long-term obligations, less current portion


      61


      14


      -


      75

        Long-term deferred contract revenue


      451


      -


      (3)


      448

        Total stockholders' equity before noncontrolling interest


      1,955


      479


      (1,057)


      1,377

        Noncontrolling interest in Akcea Therapeutics, Inc.


      -


      -


      218


      218

        Total stockholders' equity


      $1,955


      $479


      $(839)


      $1,595

           Total liabilities and stockholders' equity


      $3,398


      $528


      $(847)


      $3,079

      SOURCE Ionis Pharmaceuticals, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.